Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5

PO Hedlund; JE Damber; I Hagerman; S Haukaas; P Henriksson; P Iversen; R Johansson; P Klarskov; F Lundbeck; F Rasmussen; E Varenhorst; J Viitanen; Teuvo Tammela

doi:10.1080/00365590801943274

Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5

PO Hedlund, JE Damber, I Hagerman, S Haukaas, P Henriksson, P Iversen, R Johansson, P Klarskov, F Lundbeck, F Rasmussen, E Varenhorst, J Viitanen, Teuvo Tammela

Research output: Contribution to journal › Article › Scientific › peer-review

54 Citations (Scopus)

Original language	English
Pages (from-to)	220-229
Journal	Scand J Urol Nephrol
Volume	42
Issue number	3
DOIs	https://doi.org/10.1080/00365590801943274
Publication status	Published - 2008
Publication type	A1 Journal article-refereed

Keywords

cardiovascular complications
combined androgen deprivation
parenteral estrogen
prostate cancer
skeletal metastases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/00365590801943274

Cite this

Hedlund, PO., Damber, JE., Hagerman, I., Haukaas, S., Henriksson, P., Iversen, P., Johansson, R., Klarskov, P., Lundbeck, F., Rasmussen, F., Varenhorst, E., Viitanen, J., & Tammela, T. (2008). Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol, 42(3), 220-229. https://doi.org/10.1080/00365590801943274

@article{92f1d4ae4c344a94be080b86332d6532,

title = "Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5",

keywords = "cardiovascular complications, combined androgen deprivation, parenteral estrogen, prostate cancer, skeletal metastases, cardiovascular complications, combined androgen deprivation, parenteral estrogen, prostate cancer, skeletal metastases",

author = "PO Hedlund and JE Damber and I Hagerman and S Haukaas and P Henriksson and P Iversen and R Johansson and P Klarskov and F Lundbeck and F Rasmussen and E Varenhorst and J Viitanen and Teuvo Tammela",

year = "2008",

doi = "10.1080/00365590801943274",

language = "English",

volume = "42",

pages = "220--229",

number = "3",

}

Hedlund, PO, Damber, JE, Hagerman, I, Haukaas, S, Henriksson, P, Iversen, P, Johansson, R, Klarskov, P, Lundbeck, F, Rasmussen, F, Varenhorst, E, Viitanen, J & Tammela, T 2008, 'Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5', Scand J Urol Nephrol, vol. 42, no. 3, pp. 220-229. https://doi.org/10.1080/00365590801943274

Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. / Hedlund, PO; Damber, JE; Hagerman, I et al.
In: Scand J Urol Nephrol, Vol. 42, No. 3, 2008, p. 220-229.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5

AU - Hedlund, PO

AU - Damber, JE

AU - Hagerman, I

AU - Haukaas, S

AU - Henriksson, P

AU - Iversen, P

AU - Johansson, R

AU - Klarskov, P

AU - Lundbeck, F

AU - Rasmussen, F

AU - Varenhorst, E

AU - Viitanen, J

AU - Tammela, Teuvo

PY - 2008

Y1 - 2008

KW - cardiovascular complications

KW - combined androgen deprivation

KW - parenteral estrogen

KW - prostate cancer

KW - skeletal metastases

KW - cardiovascular complications

KW - combined androgen deprivation

KW - parenteral estrogen

KW - prostate cancer

KW - skeletal metastases

U2 - 10.1080/00365590801943274

DO - 10.1080/00365590801943274

M3 - Article

SN - 0036-5599

VL - 42

SP - 220

EP - 229

JO - Scand J Urol Nephrol

JF - Scand J Urol Nephrol

IS - 3

ER -